<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 18 Nov 2024 10:12:35 +0000</lastbuilddate>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39551940/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 18:ehae795. doi: 10.1093/eurheartj/ehae795. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39551940/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39551940</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae795>10.1093/eurheartj/ehae795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39551940</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>William A E Parker</dc:creator>
<dc:creator>Robert F Storey</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding</dc:title>
<dc:identifier>pmid:39551940</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae795</dc:identifier>
</item>
<item>
<title>Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39551938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients treated with oral anticoagulants for VTE had a more than two-fold increased bleeding rate when using NSAIDs. This increased bleeding rate was not restricted to the gastrointestinal tract.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 18:ehae736. doi: 10.1093/eurheartj/ehae736. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The bleeding risk of using non-steroidal anti-inflammatory drugs (NSAIDs) in patients treated with oral anticoagulants for venous thromboembolism (VTE) remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nationwide cohort study of 51 794 VTE patients initiating oral anticoagulants between 1 January 2012 and 31 December 2022 was conducted. Time-dependent multivariate cause-specific Cox regression was used to compute adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Event rates for any bleeding per 100 person-years were 3.5 [95% confidence interval (CI), 3.4-3.7] during periods without NSAID use and 6.3 (95% CI, 5.1-7.9) during periods with NSAID use (number needed to harm = 36 patients treated for 1 year). Compared with non-use, the adjusted hazard ratios for any bleeding associated with NSAID use were 2.09 (95% CI, 1.67-2.62) overall, 1.79 (95% CI, 1.36-2.36) for ibuprofen, 3.30 (95% CI, 1.82-5.97) for diclofenac, and 4.10 (95% CI, 2.13-7.91) for naproxen. Compared with non-use, the adjusted hazard ratios associated with NSAID use were 2.24 (95% CI, 1.61-3.11) for gastrointestinal bleeding, 3.22 (95% CI, 1.69-6.14) for intracranial bleeding, 1.36 (95% CI, .67-2.77) for thoracic and respiratory tract bleeding, 1.57 (95% CI, .98-2.51) for urinary tract bleeding, and 2.99 (95% CI, 1.45-6.18) for anaemia caused by bleeding. Results were consistent for anticoagulant and VTE subtypes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients treated with oral anticoagulants for VTE had a more than two-fold increased bleeding rate when using NSAIDs. This increased bleeding rate was not restricted to the gastrointestinal tract.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39551938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39551938</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae736>10.1093/eurheartj/ehae736</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39551938</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Søren Riis Petersen</dc:creator>
<dc:creator>Kasper Bonnesen</dc:creator>
<dc:creator>Erik Lerkevang Grove</dc:creator>
<dc:creator>Lars Pedersen</dc:creator>
<dc:creator>Morten Schmidt</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study</dc:title>
<dc:identifier>pmid:39551938</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae736</dc:identifier>
</item>
<item>
<title>Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39551169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among adults with T2D, an ILI led to a significant reduction in hs-cTnT on follow-up but a transient increase in NT-proBNP levels at 1-year that attenuated over time. Longitudinal assessment of NT-proBNP and hs-cTnT provide prognostic information for ASCVD risk while only changes in NT-proBNP predicted HF risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10417-2. doi: 10.1016/j.jacc.2024.11.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: NT-proBNP and hs-cTnT are associated with cardiovascular outcomes and are recommended for measurement in type 2 diabetes (T2D). However, the effects of an intensive lifestyle intervention (ILI) targeting weight loss on cardiac biomarkers and the prognostic association of changes in these biomarkers with risk of adverse cardiovascular outcomes in T2D are not well-established.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To evaluate the effects of an ILI on cardiac biomarkers and the association of changes in cardiac biomarkers with risk of cardiovascular outcomes in T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants of the LookAHEAD trial underwent NT-proBNP and hs-cTnT measurement at baseline (N=3,984), 1- and 4-years. The effects of the ILI (vs. diabetes support and education [DSE]) on cardiac biomarkers were assessed using adjusted linear mixed-effect models and summarized as geometric mean ratios (GMR). Associations of longitudinal changes in cardiac biomarkers with risk of cardiovascular outcomes were assessed using adjusted Cox models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Average baseline NT-proBNP and hs-cTnT was 77 and 10.7 ng/L, respectively. The ILI (vs. DSE) led to an increase in NT-proBNP at 1-year (GMR[95% CI]: 1.14[1.08-1.20]), but this difference was attenuated by 4-years (GMR[95% CI]: 1.01[0.96-1.07]). The ILI (vs. DSE) led to lower hs-cTnT at 1-year (GMR[95% CI]: 0.94[0.91-0.97]) and 4-years (GMR[95% CI]: 0.93 [0.90-0.96]). Participants with meaningful weight loss by 1-year (≥5% vs. &lt;5%) had a significant increase in NT-proBNP in the short-term (year-1) which attenuated in the long-term follow-up (year-4). Meaningful 1-year weight loss was significantly associated with reduction in hs-cTnT in the long-term. In adjusted Cox-models, increase in NT-proBNP was significantly associated with higher risk of the composite ASCVD outcome and HF independent of baseline measure of the cardiac biomarker and changes in risk factors. In contrast, longitudinal increase in hs-cTnT was significantly associated with higher risk of the composite ASCVD outcome but not HF in the most adjusted model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among adults with T2D, an ILI led to a significant reduction in hs-cTnT on follow-up but a transient increase in NT-proBNP levels at 1-year that attenuated over time. Longitudinal assessment of NT-proBNP and hs-cTnT provide prognostic information for ASCVD risk while only changes in NT-proBNP predicted HF risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39551169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39551169</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.004>10.1016/j.jacc.2024.11.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39551169</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kershaw V Patel</dc:creator>
<dc:creator>Zainali Chunawala</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Matthew W Segar</dc:creator>
<dc:creator>Katelyn R Garcia</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Thomas J Wang</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Alain G Bertoni</dc:creator>
<dc:creator>Mark Espeland</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study</dc:title>
<dc:identifier>pmid:39551169</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.004</dc:identifier>
</item>
<item>
<title>Understanding The Impact of Vertical Integration on Cardiovascular Care Quality: A Complex and Worthwhile Endeavor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39551168/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 8:S0735-1097(24)10428-7. doi: 10.1016/j.jacc.2024.11.013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39551168/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39551168</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.013>10.1016/j.jacc.2024.11.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39551168</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel M Blumenthal</dc:creator>
<dc:creator>John Hsu</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding The Impact of Vertical Integration on Cardiovascular Care Quality: A Complex and Worthwhile Endeavor</dc:title>
<dc:identifier>pmid:39551168</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.013</dc:identifier>
</item>
<item>
<title>Treating Older Patients in Cardiogenic Shock with a Microaxial Flow Pump: Is it DANGERous?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39551167/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This exploratory secondary analysis of the DanGer Shock trial demonstrates that elderly patients with STEMI-related CS experience high mortality and may not attain the same benefit from routine treatment with a mAFP as younger patients. Incorporating age as a factor in patient selection may enhance the overall benefit of this therapy. (DanGer Shock, NCT01633502).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10416-0. doi: 10.1016/j.jacc.2024.11.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Whether age impacts the recently demonstrated survival benefit of microaxial flow pump (mAFP) treatment in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the impact of age on mortality and complication rates in patients with STEMI-related CS randomized to standard care or mAFP on top of standard care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a secondary analysis of the Danish-German Cardiogenic Shock (DanGer Shock) trial, an international, multicenter, open-label trial, in which 355 adult patients with STEMI-related CS were randomized to receive a mAFP (Impella CP) plus standard care or standard care alone. The primary outcome of 180-day all-cause mortality is analysed according to age and intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From lowest to highest age quartile, the median ages (range) were: 54 (31-59), 65 (60-69), 73 (70-76), and 81 (77-92) years. There were no differences in blood pressure, lactate level, left ventricular ejection fraction or shock severity at randomization across age groups. Mortality increased from lowest to highest quartile (31%, 47%, 61%, and 73%, respectively; log-rank p&lt;0.001), with an adjusted odds ratio (OR) for death at 180 days of 7.85 (95% CI, 3.37-19.2; p&lt;0.001) in the highest quartile compared to the lowest. The predicted risk of mortality was higher in the standard-care group until approximately 77 years, after which the predicted risk became higher in the mAFP group (p-interaction=0.2). In patients younger than 77 years, a reduced 180-day mortality was observed in patients randomized to the mAFP (OR, 0.45; 95% CI, 0.28-0.73; p=0.001), opposed to patients aged 77 years or older (OR, 1.52; 95% CI, 0.57-4.08; p=0.40), p=0.028 for interaction. Complications were more frequent in the mAFP group, but there were no apparent differences in incidence of complications across all ages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This exploratory secondary analysis of the DanGer Shock trial demonstrates that elderly patients with STEMI-related CS experience high mortality and may not attain the same benefit from routine treatment with a mAFP as younger patients. Incorporating age as a factor in patient selection may enhance the overall benefit of this therapy. (DanGer Shock, NCT01633502).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39551167/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39551167</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.003>10.1016/j.jacc.2024.11.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39551167</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Anika Klein</dc:creator>
<dc:creator>Rasmus P Beske</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Lisette O Jensen</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Norman Mangner</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Vasileios Panoulas</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Nikos Werner</dc:creator>
<dc:creator>Thomas Engstøm</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Anders Junker</dc:creator>
<dc:creator>Henrik Schmidt</dc:creator>
<dc:creator>Christian J Terkelsen</dc:creator>
<dc:creator>Jacob E Møller</dc:creator>
<dc:creator>DanGer Shock Investigators</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Treating Older Patients in Cardiogenic Shock with a Microaxial Flow Pump: Is it DANGERous?</dc:title>
<dc:identifier>pmid:39551167</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.003</dc:identifier>
</item>
<item>
<title>Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, decline in kidney function was frequent in patients with ATTR-CM and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4578. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of changes in kidney function over time has yet to be defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the prognostic importance of a decline in estimated glomerular filtration rate (eGFR) in a large cohort of patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This retrospective, observational, single-center cohort study evaluated patients diagnosed with ATTR-CM at the National Amyloidosis Centre (NAC) in the UK who underwent an eGFR baseline assessment and a follow-up assessment at 1 year between January 2000 and April 2024. Data analysis was performed in June 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was the risk of all-cause mortality associated with decline in kidney function (defined as a decrease in eGFR >;20%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2001 patients, mean (SD) age was 75.5 (8.4) years, and 263 patients (13.1%) were female. The median (IQR) change in eGFR was -5 mlL/min/1.73 m2 (-12 to 1), and 481 patients (24.0%) experienced decline in kidney function. Patients who experienced decline in kidney function more often had the p.(V142I) genotype than patients with stable kidney function (99 [20.6%] vs 202 [13.3%]; P &lt; .001) and had a more severe cardiac phenotype at baseline, as evidenced by higher median (IQR) concentrations of serum cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP]: 2949 pg/mL [1759-5182] vs 2309 pg/mL [1146-4290]; P &lt; .001; troponin T: 0.060 ng/mL [0.042-0.086] vs 0.052 ng/mL [0.033-0.074]; P &lt; .001), while baseline median (IQR) kidney function was similar between the 2 groups (eGFR: 63 mL/min/1.73 m2 [51-77] vs 61 mL/min/1.73 m2 [49-77]; P = .41). Decline in kidney function was associated with a 1.7-fold higher risk of mortality (hazard ratio [HR], 1.71; 95% CI, 1.43-2.04; P &lt; .001), with a similar risk across the 3 genotypes (wild type: HR, 1.64; 95% CI, 1.31-2.04; p.(V142I): HR, 1.70; 95% CI, 1.21-2.39; non-p.(V142I): HR, 1.51; 95% CI, 0.87-2.61) (P for interaction = .93) and the 3 NAC disease stages (stage 1: HR, 1.69; 95% CI, 1.22-2.32; stage 2: HR, 1.69; 95% CI, 1.30-2.18; stage 3: HR, 1.61; 95% CI, 1.11-2.35) (P for interaction = .97). Decline in kidney function remained independently associated with mortality after adjusting for increases in NT-proBNP and outpatient diuretic intensification (HR, 1.48; 95% CI, 1.23-2.76; P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, decline in kidney function was frequent in patients with ATTR-CM and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550765</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4578>10.1001/jamacardio.2024.4578</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550765</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>Salsabeel Kazi</dc:creator>
<dc:creator>Ali Pasyar</dc:creator>
<dc:creator>Carina M Luxhøj</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>William Moody</dc:creator>
<dc:creator>Richard P Steeds</dc:creator>
<dc:creator>Brett W Sperry</dc:creator>
<dc:creator>Ronald M Witteles</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Ashutosh Wechalekar</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:39550765</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4578</dc:identifier>
</item>
<item>
<title>The Fine Art and Science of Translating Trials Results Into Clinical Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4550. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550722</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4550>10.1001/jamacardio.2024.4550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550722</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Fine Art and Science of Translating Trials Results Into Clinical Practice</dc:title>
<dc:identifier>pmid:39550722</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4550</dc:identifier>
</item>
<item>
<title>Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4613. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Sex is associated with the clinical presentation, outcomes, and response to treatment in patients with heart failure (HF). However, little is known about the safety and efficacy of treatment with finerenone according to sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To estimate the efficacy and safety of finerenone compared with placebo in both women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF). The trial was conducted across 653 sites in 37 countries. Participants were adults aged 40 years and older with symptomatic HF and left ventricular ejection fraction (LVEF) of 40% or greater randomized between September 2020 and January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events (unplanned HF hospitalizations or urgent HF visits).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 patients were randomized in FINEARTS-HF, of whom 2732 were women (45.5%), with a mean (SD) age of 73.6 (9.1) years. Women had higher rates of any obesity, higher LVEF (54.6 [7.6%] vs 50.9 [7.6] for men), lower mean (SD) estimated glomerular filtration rate than men (59.7 [19.1] vs 64.1 [20.0] for men; P&lt;.001) , worse New York Heart Association functional class, and lower Kansas City Cardiomyopathy Questionnaire-Total Symptom Scores (KCCQ-TSS) (mean [SD] 62.3 [24.0] vs 71.0 [23.1]). The incident rate of the primary outcome was slightly lower in women (15.7; 95% CI, 14.3-17.3) than in men (16.8; 95% CI, 15.4-18.3) per 100 person-years. Compared with placebo, finerenone reduced the risk of the primary end point similarly in women and men: rate ratio 0.78 (95% CI, 0.65-0.95) in women and 0.88 (95% CI, 0.74-1.04) in men (P = .41 for interaction). Consistent effects were observed for the components of the primary outcome and all-cause mortality. The mean increase (improvement) in KCCQ-TSS from baseline to 12 months was greater with finerenone, regardless of sex (P = .73 for interaction). Finerenone had similar tolerability in women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550721</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4613>10.1001/jamacardio.2024.4613</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550721</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Misato Chimura</dc:creator>
<dc:creator>Xiaowen Wang</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Cândida Fonseca</dc:creator>
<dc:creator>Eva Goncalvesova</dc:creator>
<dc:creator>Tzvetana Katova</dc:creator>
<dc:creator>Katharina Mueller</dc:creator>
<dc:creator>Andrea Glasauer</dc:creator>
<dc:creator>Katja Rohwedder</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Savina Nodari</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Clara Inés Saldarriaga</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39550721</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4613</dc:identifier>
</item>
<item>
<title>Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that partial cardiac denervation was an effective procedure to reduce the occurrence of POAF after isolated CABG without additional postoperative complications. These results suggest that partial cardiac denervation may be a good option for cardiac surgeons to consider for preventing POAF after CABG.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4639. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Efficient approaches to prevent postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) are still needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether partial cardiac denervation, achieved by cutting off the ligament of Marshall (LOM) and resecting the fat pad along the Waterston groove, can reduce the risk of POAF following CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING AND PARTICIPANTS: This single-center, randomized clinical trial enrolled adult patients scheduled for isolated CABG in China. Enrollment was from August 15, 2022, to December 13, 2023; follow-up visits were 30 days after discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants were randomized into the intervention group (CABG plus partial cardiac denervation) and the control group (CABG only) in a 1:1 pattern. All participants were continuously monitored for the incidence of POAF until day 6 after the operation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary end point was the incidence of POAF in 6 days, defined as a supraventricular arrhythmia lasting for more than 30 seconds.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial enrolled 430 patients (79 [18.4%] female; mean [SD] age, 61.9 [7.8] years). Compared with the control group, the 6-day incidence of POAF was significantly lower in the intervention group (18.1% vs 31.6%; P = .001; risk ratio, 0.57 [95% CI, 0.41-0.81]). To further support these results, a sensitivity analysis performed with Kaplan-Meier survival curves also showed a significant reduction in the occurrence of POAF in the intervention group (hazard ratio, 0.53 [95% CI, 0.36-0.79]; P = .002). Safety assessments showed no difference between the 2 groups, while postoperative medical cost was reduced in the intervention group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that partial cardiac denervation was an effective procedure to reduce the occurrence of POAF after isolated CABG without additional postoperative complications. These results suggest that partial cardiac denervation may be a good option for cardiac surgeons to consider for preventing POAF after CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05009914.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550720</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4639>10.1001/jamacardio.2024.4639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550720</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ziang Yang</dc:creator>
<dc:creator>Xieraili Tiemuerniyazi</dc:creator>
<dc:creator>Fei Xu</dc:creator>
<dc:creator>Yang Wang</dc:creator>
<dc:creator>Yang Sun</dc:creator>
<dc:creator>Peng Yan</dc:creator>
<dc:creator>Liangxin Tian</dc:creator>
<dc:creator>Chao Han</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Shiwei Pan</dc:creator>
<dc:creator>Zhan Hu</dc:creator>
<dc:creator>Xi Li</dc:creator>
<dc:creator>Wei Zhao</dc:creator>
<dc:creator>Wei Feng</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39550720</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4639</dc:identifier>
</item>
<item>
<title>Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4624. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550719</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4624>10.1001/jamacardio.2024.4624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550719</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sadiya Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step</dc:title>
<dc:identifier>pmid:39550719</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4624</dc:identifier>
</item>
<item>
<title>Power of Digital Nudges to Boost Influenza Vaccination Rates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4692. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550718</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4692>10.1001/jamacardio.2024.4692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550718</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mohammad Madjid</dc:creator>
<dc:creator>Payam Safavi-Naeini</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Power of Digital Nudges to Boost Influenza Vaccination Rates</dc:title>
<dc:identifier>pmid:39550718</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4692</dc:identifier>
</item>
<item>
<title>Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Across 3 nationwide RCTs of Danish citizens, messaging emphasizing the cardiovascular benefits of vaccination improved influenza vaccination uptake, with greater benefits observed in patients with a history of AMI. This low-cost, scalable implementation strategy should be considered to encourage influenza vaccination in high-risk patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4648. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Influenza vaccination in patients with acute myocardial infarction (AMI) reduces major adverse cardiac events and is strongly recommended in clinical practice guidelines. Effective strategies to improve vaccination are needed in these high-risk patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate whether electronically delivered behavioral nudges improve influenza vaccine uptake in patients with AMI across 3 nationwide implementation randomized clinical trials (RCTs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake (NUDGE-FLU), Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing Influenza Vaccine Uptake Among Older Adults (NUDGE-FLU-2), and Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake Among Adults With Chronic Disease (NUDGE-FLU-CHRONIC) were RCTs conducted during the 2022 to 2023 and 2023 to 2024 influenza seasons in Denmark. Participants were randomized to either usual care or various behaviorally informed, electronically delivered, letter-based nudges. In a prespecified participant-level pooled meta-analysis, interaction of AMI status on the effects of letter-based nudges vs usual care was examined. Pooled treatment effects were estimated using binomial regression models with identity link, adjustment for trial, and 2-way clustered SEs at the household and participant levels. Effect modification by recency of AMI as a continuous variable was assessed using restricted cubic spline modeling in NUDGE-FLU-CHRONIC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Behaviorally informed, electronically delivered, letter-based nudges or usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary end point was influenza vaccination receipt.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2 146 124 individual randomizations (mean [SD] age, 71.1 [11.6] years; 1 114 725 female [51.9%]) across all 3 trials, 59 458 (2.8%) had a history of AMI. Improvement in vaccine uptake was similar in patients with vs without a history of AMI who received any nudge letter compared with usual care (+1.81 vs +1.32 percentage points; P for interaction by AMI status = .09). A letter highlighting the cardiovascular benefits of vaccination (ie, cardiovascular-gain frame) resulted in larger improvements in vaccine uptake among patients with (vs without) a history of AMI (+3.91 vs +2.03 percentage points; P for interaction by AMI status = .002). Among patients with AMI, the benefits of the cardiovascular-gain frame letter were more pronounced in those not vaccinated in the prior season (+13.7 vs +1.48 percentage points; P for interaction &lt;.001). Among younger participants with chronic disease, the cardiovascular-gain frame letter was particularly effective in patients with more recent AMI (P for interaction by continuous recency of AMI &lt;.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Across 3 nationwide RCTs of Danish citizens, messaging emphasizing the cardiovascular benefits of vaccination improved influenza vaccination uptake, with greater benefits observed in patients with a history of AMI. This low-cost, scalable implementation strategy should be considered to encourage influenza vaccination in high-risk patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT05542004, NCT06030726, NCT06030739.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550717</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4648>10.1001/jamacardio.2024.4648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550717</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Manan Pareek</dc:creator>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Kira Hyldekær Janstrup</dc:creator>
<dc:creator>Carsten Schade Larsen</dc:creator>
<dc:creator>Lykke Larsen</dc:creator>
<dc:creator>Lothar Wiese</dc:creator>
<dc:creator>Michael Dalager-Pedersen</dc:creator>
<dc:creator>Erica L Dueger</dc:creator>
<dc:creator>Sandrine Samson</dc:creator>
<dc:creator>Matthew M Loiacono</dc:creator>
<dc:creator>Rebecca C Harris</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Cyril Jean-Marie Martel</dc:creator>
<dc:creator>Pradeesh Sivapalan</dc:creator>
<dc:creator>Jens Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:39550717</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4648</dc:identifier>
</item>
<item>
<title>Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4539. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with increased levels of serum potassium in follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the frequency and predictors of serum potassium level greater than 5.5 mmol/L and less than 3.5 mmol/L and examine the treatment effect associated with finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of the FINEARTS-HF multicenter, randomized clinical trial, performed between September 14, 2020, and January 10, 2023, with a median follow-up of 32 months (final date of follow-up: June 14, 2024). Patients with heart failure and left ventricular ejection fraction greater than or equal to 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants received finerenone or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of total worsening heart failure events or cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 participants were included (3003 randomized to receive finerenone and 2998 randomized to receive placebo). The increase in serum potassium was greater in the finerenone group than the placebo group at 1 month (median [IQR] difference, 0.19 [0.17-0.21] mmol/L) and 3 months (median [IQR] difference, 0.23 [0.21-0.25] mmol/L), which persisted for the remainder of trial follow-up. Finerenone increased the risks of potassium level increasing to greater than 5.5 mmol/L (hazard ratio [HR], 2.16 [95% CI, 1.83-2.56]; P &lt; .001) and decreased the risks for potassium level decreasing to less than 3.5 mmol/L (HR, 0.46 [95% CI, 0.38-0.56]; P &lt; .001). Both low (&lt; 3.5 mmol/L; HR, 2.49 [95% CI, 1.8-3.43]) and high (>;5.5 mmol/L; HR, 1.64 [95% CI, 1.04-2.58]) potassium levels were associated with higher subsequent risks of the primary outcome in both treatment groups. Nevertheless, the risk of the primary outcome was generally lower in patients treated with finerenone compared with placebo, even in those whose potassium level increased to greater than 5.5 mmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39550716</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4539>10.1001/jamacardio.2024.4539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550716</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Mehmet Birhan Yilmaz</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Andrea Horvat-Broecker</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39550716</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4539</dc:identifier>
</item>
<item>
<title>The Arabidopsis blue-light photoreceptor CRY2 is active in darkness to inhibit root growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>Cryptochromes (CRYs) are blue-light receptors that regulate diverse aspects of plant growth. However, whether and how non-photoexcited CRYs function in darkness or non-blue-light conditions is unknown. Here, we show that CRY2 affects the Arabidopsis transcriptome even in darkness, revealing a non-canonical function. CRY2 suppresses cell division in the root apical meristem to downregulate root elongation in darkness. Blue-light oligomerizes CRY2 to de-repress root elongation. CRY2 physically...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 8:S0092-8674(24)01213-3. doi: 10.1016/j.cell.2024.10.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cryptochromes (CRYs) are blue-light receptors that regulate diverse aspects of plant growth. However, whether and how non-photoexcited CRYs function in darkness or non-blue-light conditions is unknown. Here, we show that CRY2 affects the Arabidopsis transcriptome even in darkness, revealing a non-canonical function. CRY2 suppresses cell division in the root apical meristem to downregulate root elongation in darkness. Blue-light oligomerizes CRY2 to de-repress root elongation. CRY2 physically interacts with FORKED-LIKE 1 (FL1) and FL3, and these interactions are inhibited by blue light, with only monomeric but not dimeric CRY2 able to interact. FL1 and FL3 associate with the chromatin of cell division genes to facilitate their transcription. This pro-growth activity is inhibited by CRY2's physical interaction with FLs in darkness. Plants have evolved to perceive both blue-light and dark cues to coordinate activation and repression of competing developmental processes in above- and below-ground organs through economical and dichotomous use of ancient light receptors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549699</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.031>10.1016/j.cell.2024.10.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549699</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Desheng Zeng</dc:creator>
<dc:creator>Junqing Lv</dc:creator>
<dc:creator>Xu Li</dc:creator>
<dc:creator>Hongtao Liu</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The Arabidopsis blue-light photoreceptor CRY2 is active in darkness to inhibit root growth</dc:title>
<dc:identifier>pmid:39549699</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.031</dc:identifier>
</item>
<item>
<title>The single-molecule accessibility landscape of newly replicated mammalian chromatin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>We present replication-aware single-molecule accessibility mapping (RASAM), a method to nondestructively measure replication status and protein-DNA interactions on chromatin genome-wide. Using RASAM, we uncover a genome-wide state of single-molecule "hyperaccessibility" post-replication that resolves over several hours. Combining RASAM with cellular models for rapid protein degradation, we demonstrate that histone chaperone CAF-1 reduces nascent chromatin accessibility by filling...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01255-8. doi: 10.1016/j.cell.2024.10.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We present replication-aware single-molecule accessibility mapping (RASAM), a method to nondestructively measure replication status and protein-DNA interactions on chromatin genome-wide. Using RASAM, we uncover a genome-wide state of single-molecule "hyperaccessibility" post-replication that resolves over several hours. Combining RASAM with cellular models for rapid protein degradation, we demonstrate that histone chaperone CAF-1 reduces nascent chromatin accessibility by filling single-molecular "gaps" and generating closely spaced dinucleosomes on replicated DNA. At cis-regulatory elements, we observe unique modes by which nascent chromatin hyperaccessibility resolves: at CCCTC-binding factor (CTCF)-binding sites, CTCF and nucleosomes compete, reducing CTCF occupancy and motif accessibility post-replication; at active transcription start sites, high chromatin accessibility is maintained, implying rapid re-establishment of nucleosome-free regions. Our study introduces a new paradigm for studying replicated chromatin fiber organization. More broadly, we uncover a unique organization of newly replicated chromatin that must be reset by active processes, providing a substrate for epigenetic reprogramming.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549698</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.039>10.1016/j.cell.2024.10.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549698</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Megan S Ostrowski</dc:creator>
<dc:creator>Marty G Yang</dc:creator>
<dc:creator>Colin P McNally</dc:creator>
<dc:creator>Nour J Abdulhay</dc:creator>
<dc:creator>Simai Wang</dc:creator>
<dc:creator>Keerthi Renduchintala</dc:creator>
<dc:creator>Iryna Irkliyenko</dc:creator>
<dc:creator>Alva Biran</dc:creator>
<dc:creator>Brandon T L Chew</dc:creator>
<dc:creator>Ayush D Midha</dc:creator>
<dc:creator>Emily V Wong</dc:creator>
<dc:creator>Jonathan Sandoval</dc:creator>
<dc:creator>Isha H Jain</dc:creator>
<dc:creator>Anja Groth</dc:creator>
<dc:creator>Elphège P Nora</dc:creator>
<dc:creator>Hani Goodarzi</dc:creator>
<dc:creator>Vijay Ramani</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The single-molecule accessibility landscape of newly replicated mammalian chromatin</dc:title>
<dc:identifier>pmid:39549698</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.039</dc:identifier>
</item>
<item>
<title>Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>Stress induces aversive memory overgeneralization, a hallmark of many psychiatric disorders. Memories are encoded by a sparse ensemble of neurons active during an event (an engram ensemble). We examined the molecular and circuit processes mediating stress-induced threat memory overgeneralization in mice. Stress, acting via corticosterone, increased the density of engram ensembles supporting a threat memory in lateral amygdala, and this engram ensemble was reactivated by both specific and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01216-9. doi: 10.1016/j.cell.2024.10.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Stress induces aversive memory overgeneralization, a hallmark of many psychiatric disorders. Memories are encoded by a sparse ensemble of neurons active during an event (an engram ensemble). We examined the molecular and circuit processes mediating stress-induced threat memory overgeneralization in mice. Stress, acting via corticosterone, increased the density of engram ensembles supporting a threat memory in lateral amygdala, and this engram ensemble was reactivated by both specific and non-specific retrieval cues (generalized threat memory). Furthermore, we identified a critical role for endocannabinoids, acting retrogradely on parvalbumin-positive (PV+) lateral amygdala interneurons in the formation of a less-sparse engram and memory generalization induced by stress. Glucocorticoid receptor antagonists, endocannabinoid synthesis inhibitors, increasing PV+ neuronal activity, and knocking down cannabinoid receptors in lateral amygdala PV+ neurons restored threat memory specificity and a sparse engram in stressed mice. These findings offer insights into stress-induced memory alterations, providing potential therapeutic avenues for stress-related disorders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549697</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.034>10.1016/j.cell.2024.10.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549697</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sylvie L Lesuis</dc:creator>
<dc:creator>Sungmo Park</dc:creator>
<dc:creator>Annelies Hoorn</dc:creator>
<dc:creator>Asim J Rashid</dc:creator>
<dc:creator>Andrew J Mocle</dc:creator>
<dc:creator>Eric W Salter</dc:creator>
<dc:creator>Stefan Vislavski</dc:creator>
<dc:creator>Madison T Gray</dc:creator>
<dc:creator>Angelica M Torelli</dc:creator>
<dc:creator>Antonietta DeCristofaro</dc:creator>
<dc:creator>Wouter P F Driever</dc:creator>
<dc:creator>Mario van der Stelt</dc:creator>
<dc:creator>Larry S Zweifel</dc:creator>
<dc:creator>Graham L Collingridge</dc:creator>
<dc:creator>Julie L Lefebvre</dc:creator>
<dc:creator>Brandon J Walters</dc:creator>
<dc:creator>Paul W Frankland</dc:creator>
<dc:creator>Matthew N Hill</dc:creator>
<dc:creator>Sheena A Josselyn</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice</dc:title>
<dc:identifier>pmid:39549697</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.034</dc:identifier>
</item>
<item>
<title>Functional genomics of human skeletal development and the patterning of height heritability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>Underlying variation in height are regulatory changes to chondrocytes, cartilage cells comprising long-bone growth plates. Currently, we lack knowledge on epigenetic regulation and gene expression of chondrocytes sampled across the human skeleton, and therefore we cannot understand basic regulatory mechanisms controlling height biology. We first rectify this issue by generating extensive epigenetic and transcriptomic maps from chondrocytes sampled from different growth plates across developing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 7:S0092-8674(24)01256-X. doi: 10.1016/j.cell.2024.10.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Underlying variation in height are regulatory changes to chondrocytes, cartilage cells comprising long-bone growth plates. Currently, we lack knowledge on epigenetic regulation and gene expression of chondrocytes sampled across the human skeleton, and therefore we cannot understand basic regulatory mechanisms controlling height biology. We first rectify this issue by generating extensive epigenetic and transcriptomic maps from chondrocytes sampled from different growth plates across developing human skeletons, discovering novel regulatory networks shaping human bone/joint development. Next, using these maps in tandem with height genome-wide association study (GWAS) signals, we disentangle the regulatory impacts that skeletal element-specific versus global-acting variants have on skeletal growth, revealing the prime importance of regulatory pleiotropy in controlling height variation. Finally, as height is highly heritable, and thus often the test case for complex-trait genetics, we leverage these datasets within a testable omnigenic model framework to discover novel chondrocyte developmental modules and peripheral-acting factors shaping height biology and skeletal growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549696</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.040>10.1016/j.cell.2024.10.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549696</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel Richard</dc:creator>
<dc:creator>Pushpanathan Muthuirulan</dc:creator>
<dc:creator>Mariel Young</dc:creator>
<dc:creator>Loic Yengo</dc:creator>
<dc:creator>Sailaja Vedantam</dc:creator>
<dc:creator>Eirini Marouli</dc:creator>
<dc:creator>Eric Bartell</dc:creator>
<dc:creator>GIANT Consortium</dc:creator>
<dc:creator>Joel Hirschhorn</dc:creator>
<dc:creator>Terence D Capellini</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Functional genomics of human skeletal development and the patterning of height heritability</dc:title>
<dc:identifier>pmid:39549696</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.040</dc:identifier>
</item>
<item>
<title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 16:e244596. doi: 10.1001/jamacardio.2024.4596. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549275</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11569412/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">PMC11569412</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4596>10.1001/jamacardio.2024.4596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549275</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>James P MacNamara</dc:creator>
<dc:creator>Christopher M Hearon</dc:creator>
<dc:creator>Giorgio Manferdelli</dc:creator>
<dc:creator>Aman M Shah</dc:creator>
<dc:creator>Kevin G Tayon</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Satyam Sarma</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</dc:title>
<dc:identifier>pmid:39549275</dc:identifier>
<dc:identifier>pmc:PMC11569412</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4596</dc:identifier>
</item>
<item>
<title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 16. doi: 10.1161/CIRCULATIONAHA.124.072860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39549263</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072860>10.1161/CIRCULATIONAHA.124.072860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549263</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Ira J Goldberg</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:creator>Ann Mertens</dc:creator>
<dc:creator>Alexis Baass</dc:creator>
<dc:creator>Rong Zhou</dc:creator>
<dc:creator>Ma'an Muhsin</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:creator>PALISADE Study Group</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</dc:title>
<dc:identifier>pmid:39549263</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072860</dc:identifier>
</item>
<item>
<title>Family matters: health policies to tackle cardiomyopathies across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae419. doi: 10.1093/eurheartj/ehae419. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39548843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae419>10.1093/eurheartj/ehae419</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548843</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Cardiomyopathies Matter Initiative</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Family matters: health policies to tackle cardiomyopathies across Europe</dc:title>
<dc:identifier>pmid:39548843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae419</dc:identifier>
</item>
<item>
<title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241118051233&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae755. doi: 10.1093/eurheartj/ehae755. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Frailty is increasingly prevalent in people presenting with acute coronary syndrome (ACS). This high-risk group is typically excluded from trials of interventions in ACS, and there is uncertainty about the risks and benefits of invasive management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with an ACS diagnosis between 2010 and 2015 in England were identified from Hospital Episode Statistics, with linked Office for National Statistics mortality data. Frailty was defined by the Hospital Frailty Risk Score. Causal inference analysis used regional variation in revascularization as an instrumental variable to estimate average treatment effects of revascularization on cardiovascular mortality up to 5 years in people presenting with ACS and low-, intermediate-, or high-risk frailty.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 565 378 ACS patients, of whom 11.6% (n = 65 522) were at intermediate risk and 4.7% (n = 26 504) were at high risk of frailty. Intermediate and high frailty risks were associated with reduced likelihood of echocardiography, invasive angiography, or revascularization and increased likelihood of mortality and major adverse cardiovascular events compared with low frailty risk. Cardiovascular death at 5 years was 78.6%, 77.3%, and 75.7% in people at low, intermediate, and high frailty risk, respectively. Instrumental variable analysis suggested that revascularization resulted in a higher absolute reduction in cardiovascular mortality in high and intermediate frail risk patients compared with low risk at 1-year post-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241118051233&v=2.18.0.post9+e462414">39548842</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae755>10.1093/eurheartj/ehae755</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548842</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marius Roman</dc:creator>
<dc:creator>Joanne Miksza</dc:creator>
<dc:creator>Florence Yuk-Lin Lai</dc:creator>
<dc:creator>Shirley Sze</dc:creator>
<dc:creator>Katrina Poppe</dc:creator>
<dc:creator>Rob Doughty</dc:creator>
<dc:creator>Iain Squire</dc:creator>
<dc:creator>Gavin James Murphy</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</dc:title>
<dc:identifier>pmid:39548842</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae755</dc:identifier>
</item>





























</channel>
</rss>